B-intervention	0	12	Preoperative
I-intervention	13	17	FLAC
I-intervention	17	18	/
I-intervention	18	29	granulocyte
I-intervention	29	30	-
I-intervention	30	36	colony
I-intervention	36	37	-
I-intervention	37	48	stimulating
I-intervention	49	55	factor
I-intervention	56	68	chemotherapy
O	69	72	for
O	73	78	stage
O	79	81	II
O	82	88	breast
O	89	95	cancer
O	95	96	:
O	97	98	a
O	99	110	prospective
O	111	121	randomized
O	122	127	trial
O	127	128	.

O	129	141	Preoperative
O	142	154	chemotherapy
O	155	158	for
O	159	164	stage
O	165	167	II
O	168	174	breast
O	175	181	cancer
O	182	185	may
O	186	192	reduce
O	193	205	locoregional
O	206	212	tumors
O	213	216	and
O	217	225	provides
O	226	233	initial
O	234	243	treatment
O	244	247	for
O	248	256	systemic
O	257	272	micrometastases
O	272	273	.

O	274	276	We
O	277	286	conducted
O	287	288	a
O	289	300	prospective
O	300	301	,
O	302	312	randomized
O	313	318	trial
O	319	321	to
O	322	330	evaluate
O	331	334	the
O	335	342	ability
O	343	345	of
O	346	355	intensive
O	356	368	preoperative
O	369	381	chemotherapy
O	382	384	to
O	385	392	enhance
O	393	396	the
O	397	404	outcome
O	405	407	of
O	408	412	this
O	413	421	approach
O	421	422	.

B-eligibility	423	431	Patients
I-eligibility	432	436	with
I-eligibility	437	445	clinical
I-eligibility	446	451	stage
I-eligibility	452	454	II
I-eligibility	455	461	breast
I-eligibility	462	468	cancer
I-eligibility	469	470	(
I-eligibility	470	474	T2N0
I-eligibility	474	475	,
I-eligibility	476	480	T1N1
I-eligibility	480	481	,
I-eligibility	482	485	and
I-eligibility	486	490	T2N1
I-eligibility	490	491	)
O	492	496	were
O	497	510	prospectively
O	511	521	randomized
O	522	524	to
O	525	532	receive
O	533	539	either
O	540	552	preoperative
O	553	555	or
O	556	569	postoperative
O	570	582	chemotherapy
O	583	587	with
O	588	592	five
O	593	595	21
O	595	596	-
O	596	599	day
O	600	606	cycles
O	607	609	of
O	610	622	fluorouracil
O	622	623	,
O	624	634	leucovorin
O	635	642	calcium
O	642	643	,
O	644	655	doxorubicin
O	655	656	,
O	657	660	and
O	661	677	cyclophosphamide
O	678	679	(
O	679	683	FLAC
O	683	684	)
O	684	685	/
O	685	696	granulocyte
O	696	697	-
O	697	703	colony
O	703	704	-
O	704	715	stimulating
O	716	722	factor
O	722	723	.

O	724	729	Local
O	730	737	therapy
O	738	747	consisted
O	748	750	of
O	751	759	modified
O	760	767	radical
O	768	778	mastectomy
O	779	781	or
O	782	795	segmentectomy
O	795	796	/
O	796	804	axillary
O	805	815	dissection
O	815	816	/
O	816	822	breast
O	823	835	radiotherapy
O	835	836	,
O	837	846	according
O	847	849	to
O	850	857	patient
O	858	868	preference
O	868	869	.

B-total-participants	870	875	Fifty
I-total-participants	875	876	-
I-total-participants	876	881	three
O	882	887	women
O	888	892	were
O	893	903	randomized
O	904	905	(
B-intervention-participants	905	907	26
B-intervention	908	920	preoperative
I-intervention	921	933	chemotherapy
O	934	937	and
B-control-participants	938	940	27
B-control	941	954	postoperative
I-control	955	967	chemotherapy
O	967	968	)
O	968	969	.

O	970	973	The
B-outcome	974	983	objective
I-outcome	984	992	clinical
I-outcome	993	1001	response
I-outcome	1002	1006	rate
O	1007	1009	of
O	1010	1013	the
O	1014	1021	primary
O	1022	1027	tumor
O	1028	1030	to
O	1031	1043	preoperative
O	1044	1056	chemotherapy
O	1057	1060	was
B-iv-bin-percent	1061	1063	80
I-iv-bin-percent	1063	1064	%
O	1064	1065	,
O	1066	1069	and
O	1070	1073	the
B-outcome	1074	1084	pathologic
I-outcome	1085	1093	complete
I-outcome	1094	1102	response
I-outcome	1103	1107	rate
O	1108	1111	was
B-iv-bin-percent	1112	1114	20
I-iv-bin-percent	1114	1115	%
O	1115	1116	.

O	1117	1129	Preoperative
O	1130	1142	chemotherapy
O	1143	1150	reduced
O	1151	1154	the
B-outcome	1155	1162	overall
I-outcome	1163	1172	incidence
I-outcome	1173	1176	and
I-outcome	1177	1183	number
I-outcome	1184	1186	of
I-outcome	1187	1195	axillary
I-outcome	1196	1201	lymph
I-outcome	1202	1206	node
I-outcome	1207	1217	metastases
O	1217	1218	.

O	1219	1224	There
O	1225	1228	was
O	1229	1231	no
O	1232	1242	difference
O	1243	1245	in
O	1246	1249	the
B-outcome	1250	1253	use
I-outcome	1254	1256	of
I-outcome	1257	1263	breast
I-outcome	1263	1264	-
I-outcome	1264	1274	conserving
I-outcome	1275	1280	local
I-outcome	1281	1288	therapy
O	1289	1296	between
O	1297	1300	the
O	1301	1304	two
O	1305	1314	treatment
O	1315	1319	arms
O	1319	1320	.

O	1321	1326	There
O	1327	1331	were
O	1332	1334	20
B-outcome	1335	1340	local
I-outcome	1340	1341	/
I-outcome	1341	1349	regional
I-outcome	1350	1352	or
I-outcome	1353	1360	distant
I-outcome	1361	1372	recurrences
O	1373	1374	(
B-iv-bin-abs	1374	1375	9
O	1376	1388	preoperative
O	1389	1392	and
B-cv-bin-abs	1393	1395	11
O	1396	1409	postoperative
O	1409	1410	)
O	1410	1411	.

O	1412	1417	There
O	1418	1421	was
O	1422	1424	no
O	1425	1435	difference
O	1436	1438	in
O	1439	1442	the
B-outcome	1443	1450	overall
I-outcome	1451	1453	or
I-outcome	1454	1461	disease
I-outcome	1461	1462	-
I-outcome	1462	1466	free
I-outcome	1467	1475	survival
O	1476	1483	between
O	1484	1487	the
O	1488	1500	preoperative
O	1501	1504	and
O	1505	1518	postoperative
O	1519	1531	chemotherapy
O	1532	1536	arms
O	1536	1537	.

O	1538	1550	Preoperative
O	1551	1555	FLAC
O	1555	1556	/
O	1556	1567	granulocyte
O	1567	1568	-
O	1568	1574	colony
O	1574	1575	-
O	1575	1586	stimulating
O	1587	1593	factor
O	1594	1606	chemotherapy
O	1607	1610	was
O	1611	1620	effective
O	1621	1628	against
O	1629	1634	local
O	1634	1635	/
O	1635	1643	regional
O	1644	1650	tumors
O	1651	1653	in
O	1654	1659	stage
O	1660	1662	II
O	1663	1669	breast
O	1670	1676	cancer
O	1677	1680	but
O	1681	1684	was
O	1685	1694	otherwise
O	1695	1705	comparable
O	1706	1708	to
O	1709	1722	postoperative
O	1723	1735	chemotherapy
O	1735	1736	.
